SF205 **REVISOR SGS** S0205-1 1st Engrossment

## SENATE STATE OF MINNESOTA **NINETY-FOURTH SESSION**

S.F. No. 205

(SENATE AUTHORS: PORT, Mann, Maye Quade and Boldon)
OFFICIAL STATUS **DATE** 01/16/2025

Introduction and first reading Referred to Commerce and Consumer Protection

03/10/2025 688a Comm report: To pass as amended and re-refer to Health and Human Services

A bill for an act 1.1

1.4

1.5

1.7

1.9

1.10

1.11

1.12

1.13

1.14

1.15

1.16

1.17

1.18

1.19

1.20

1.21

relating to health; prohibiting prior authorization of antineoplastic cancer treatment; 1 2 amending Minnesota Statutes 2024, section 62M.07, subdivision 2. 1.3

## BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:

- Section 1. Minnesota Statutes 2024, section 62M.07, subdivision 2, is amended to read:
- Subd. 2. Prior authorization of certain services prohibited. No utilization review 1.6 organization, health plan company, or claims administrator may conduct or require prior authorization of: 1.8
  - (1) emergency confinement or an emergency service. The enrollee or the enrollee's authorized representative may be required to notify the health plan company, claims administrator, or utilization review organization as soon as reasonably possible after the beginning of the emergency confinement or emergency service;
  - (2) outpatient mental health treatment or outpatient substance use disorder treatment, except for treatment which is a medication. Prior authorizations required for medications used for outpatient mental health treatment or outpatient substance use disorder treatment must be processed according to section 62M.05, subdivision 3b, for initial determinations, and according to section 62M.06, subdivision 2, for appeals;
  - (3) antineoplastic cancer treatment that is consistent with guidelines of the National Comprehensive Cancer Network or nationally and internationally accepted standards of care, except for including but not limited to treatment which that is a medication. Prior authorizations required for medications used for antineoplastic cancer treatment must be

Section 1. 1

processed according to section 62M.05, subdivision 3b, for initial determinations, and
according to section 62M.06, subdivision 2, for appeals;
(4) services that currently have a rating of A or B from the United States Preventive
Services Task Force, immunizations recommended by the Advisory Committee on
Immunization Practices of the Centers for Disease Control and Prevention, or preventive
services and screenings provided to women as described in Code of Federal Regulations,
title 45, section 147.130;
(5) pediatric hospice services provided by a hospice provider licensed under sections
144A.75 to 144A.755; and
(6) treatment delivered through a neonatal abstinence program operated by pediatric pain or palliative care subspecialists.
Clauses (2) to (6) are effective January 1, 2026, and apply to health benefit plans offered, sold, issued, or renewed on or after that date.

**EFFECTIVE DATE.** This section is effective January 1, 2027, and applies to health

benefit plans offered, sold, issued, or renewed on or after that date.

SGS

S0205-1

1st Engrossment

SF205

2.1

2.2

2.3

2.4

2.5

2.6

2.7

2.8

2.9

2.10

2.11

2.12

2.13

2.14

2.15

REVISOR

Section 1. 2